Steven Mah
Stock Analyst at TD Cowen
(2.89)
# 1,235
Out of 4,479 analysts
22
Total ratings
36%
Success rate
12.25%
Average return
Main Sectors:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Maintains: Buy | $55 → $65 | $47.32 | +37.36% | 2 | Jun 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $7 → $3 | $0.35 | +765.80% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $7.16 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $20.33 | +106.59% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $2.77 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $3.67 | +172.48% | 1 | Feb 22, 2023 | |
| ME 23andMe Holding Co. | Initiates: Outperform | $6 | $0.39 | +1,431.39% | 1 | Sep 22, 2022 | |
| ABSI Absci | Upgrades: Outperform | n/a | $2.97 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.89 | +626.64% | 2 | Jul 15, 2022 | |
| TLIS Talis Biomedical | Downgrades: Neutral | n/a | $8.50 | - | 2 | Aug 12, 2021 | |
| NTRA Natera | Maintains: Overweight | n/a | $110.70 | - | 2 | Jul 6, 2021 | |
| AKYA Akoya Biosciences | Initiates: Overweight | n/a | $2.18 | - | 1 | May 11, 2021 | |
| FLGT Fulgent Genetics | Maintains: Overweight | n/a | $19.98 | - | 1 | Mar 5, 2021 | |
| PACB Pacific Biosciences of California | Upgrades: Overweight | n/a | $1.28 | - | 1 | Feb 11, 2021 | |
| OCX OncoCyte | Upgrades: Overweight | n/a | $2.96 | - | 1 | Dec 16, 2020 | |
| ILMN Illumina | Downgrades: Neutral | n/a | $105.51 | - | 1 | Aug 7, 2020 | |
| QDEL QuidelOrtho | Maintains: Overweight | n/a | $31.36 | - | 1 | Jul 8, 2020 |
Twist Bioscience
Jun 13, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $47.32
Upside: +37.36%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $7 → $3
Current: $0.35
Upside: +765.80%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $7.16
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $20.33
Upside: +106.59%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.77
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $3.67
Upside: +172.48%
23andMe Holding Co.
Sep 22, 2022
Initiates: Outperform
Price Target: $6
Current: $0.39
Upside: +1,431.39%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.97
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.89
Upside: +626.64%
Talis Biomedical
Aug 12, 2021
Downgrades: Neutral
Price Target: n/a
Current: $8.50
Upside: -
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: n/a
Current: $110.70
Upside: -
Akoya Biosciences
May 11, 2021
Initiates: Overweight
Price Target: n/a
Current: $2.18
Upside: -
Fulgent Genetics
Mar 5, 2021
Maintains: Overweight
Price Target: n/a
Current: $19.98
Upside: -
Pacific Biosciences of California
Feb 11, 2021
Upgrades: Overweight
Price Target: n/a
Current: $1.28
Upside: -
OncoCyte
Dec 16, 2020
Upgrades: Overweight
Price Target: n/a
Current: $2.96
Upside: -
Illumina
Aug 7, 2020
Downgrades: Neutral
Price Target: n/a
Current: $105.51
Upside: -
QuidelOrtho
Jul 8, 2020
Maintains: Overweight
Price Target: n/a
Current: $31.36
Upside: -